ARTICLE | Clinical News

Latuda lurasidone regulatory update

March 31, 2014 7:00 AM UTC

The European Commission and Australia's Therapeutic Goods Administration ( TGA) separately approved Latuda lurasidone to treat schizophrenia in adults. Latuda is a small molecule antagonist of dopamine D2 receptor, serotonin (5-HT2A) and (5-HT7) receptors and adrenergic receptor alpha 2c ( ADRA2C), and a partial agonist of serotonin (5-HT1A) receptor. Takeda has exclusive rights from Dainippon to develop and commercialize the once-daily oral product for schizophrenia and bipolar disorder in the EU, Norway, Russia, Switzerland and Turkey (see BioCentury, May 16, 2011). ...